Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P11021

UPID:
BIP_HUMAN

ALTERNATIVE NAMES:
78 kDa glucose-regulated protein; Binding-immunoglobulin protein; Heat shock protein 70 family protein 5; Heat shock protein family A member 5; Immunoglobulin heavy chain-binding protein

ALTERNATIVE UPACC:
P11021; B0QZ61; Q2EF78; Q9NPF1; Q9UK02

BACKGROUND:
Endoplasmic reticulum chaperone BiP, known for its roles in the endoplasmic reticulum's protein quality control, is pivotal in managing protein folding and misfolding. It interacts with DNAJC10/ERdj5 to ensure proper protein folding and degradation of misfolded proteins. BiP also plays a significant role in inhibiting the ERN1/IRE1-mediated unfolded protein response, crucial for cellular homeostasis.

THERAPEUTIC SIGNIFICANCE:
The exploration of Endoplasmic reticulum chaperone BiP's functions offers promising avenues for therapeutic intervention. Its critical role in protein folding and the unfolded protein response mechanism makes it a potential target for treating diseases associated with protein misfolding and endoplasmic reticulum stress.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.